Overgrowth syndromes: Is dysfunctional PI3-kinase signalling a unifying mechanism?

European Journal of Human Genetics

Volumn 11, Issue 9, 2003, Pages 665-670

  Barker, Karen T ^a   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cowden syndrome; Overgrowth; PI3 kinase; Proteus syndrome; Tuberous sclerosis

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CELL COUNT; CELL SIZE; CELLULAR DISTRIBUTION; COWDEN SYNDROME; DROSOPHILA; EXPERIMENTAL MODEL; GROWTH DISORDER; HUMAN; LEPRECHAUNISM; LYMPHEDEMA; MULTIPLE CANCER; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE GROWTH; TUBEROUS SCLEROSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH DISORDERS; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; PROTEUS SYNDROME; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

ANIMALIA;

EID: 0141478669     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201026     Document Type: Article

References (46)

1. Cohen Jr MM, Hayden PW: A newly recognized hamartomatous syndrome. Birth Defects Orig Artic Ser 1979; 15: 291-296.
2. Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E: The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983; 140: 5-12.
3. Biesecker LG, Happle R, Mulliken JB et al: Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet 1999; 84: 389-395.
4. Happle R: Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 1987; 16: 899-906.
5. Stocker H, Hafen E: Genetic control of cell size. Curr Opin Genet Dev 2000; 10: 529-535.
6. Potter CJ, Xu T: Mechanisms of size control. Curr Opin Genet Dev 2001; 11: 279-286.
7. Dufner A, Thomas G: Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253: 100-109.
8. Kwiatkowski DJ, Zhang H, Bandura JL et al: A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525-534.
9. Goncharova EA, Goncharov DA, Eszterhas A et al: Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002; 277: 30958-30967.
10. Potter CJ, Pedraza LG, Xu T: Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002; 4: 658-665.
11. Gao X, Zhang Y, Arrazola P et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002; 4: 699-704.
12. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-657.
13. Shepherd PR, Withers DJ, Siddle K: Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998; 333: 471-490.
14. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
15. Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-254.
16. Scheid MP, Marignani PA, Woodgett JR: Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 2000; 22: 6247-6260.
17. Rychlik W, Domier LL, Gardner PR, Hellmann GM, Rhoads RE: Amino acid sequence of the mRNA cap-binding protein from human tissues. Proc Nat Acad Sci USA 1987; 84: 945-949.
18. Coelho CM, Leevers SJ: Do growth and cell division rates determine cell size in multicellular organisms? J Cell Sci 2000; 113: 2927-2934.
19. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G: Drosophila S6 kinase: a regulator of cell size. Science 1999; 285: 2126-2129.
20. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5- trisphosphate. J Biol Chem 1998; 273: 13375-13378.
21. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998; 95: 15587-15591.
22. Huang H, Potter CJ, Tao W et al: PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development 1999; 126: 5365-5372.
23. Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001; 15: 1383-1392.
24. Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001; 105: 357-368.
25. Shioi T, Kang PM, Douglas PS et al: The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19: 2537-2548.
26. Shioi T, McMullen JR, Kang PM et al: Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002; 22: 2799-2809.
27. Kwon CH, Zhu X, Zhang J et al: Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001; 29: 404-411.
28. Backman SA, Stambolic V, Suzuki A et al: Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001; 29: 396-403.
29. Groszer M, Erickson R, Scripture-Adams DD et al: Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001; 294: 2186-2189.
30. Xu Z, Stokoe D, Kane LP, Weiss A: The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ 2002; 13: 285-296.
31. Grønning LM, Cederberg A, Miura N, Enerback S, Tasken K: Insulin and TNF alpha induce expression of the forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Mol Endocrinol. 2002; 6: 873-883.
32. Kurotaki N, Imaizumi K, Harada N et al: Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002; 30: 365-366.
33. Albrecht S, Haber RM, Goodman JC, Duvic M: Cowden syndrome and Lhermitte-Duclos disease. Cancer 1992; 70: 869-876.
34. Pascual-Castroviejo I, Patron M, Gutierrez M, Carceller F, Pascual-Pascual SI: Tuberous sclerosis associated with histologically confirmed ocular and cerebral tumors. Pediatr Neurol 1995; 13: 172-174.
35. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355.
36. Suzuki A, de la Pompa JL, Stambolic V et al: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178.
37. Rudolph G, Blum WF, Jenne EW et al: Growth hormone (GH), insulin-like growth factors (IGFs), and IGF-binding protein-3 (IGFBP-3) in a child with Proteus syndrome. Am J Med Genet 1994; 50: 204-210.
38. Hoeflich A, Weber MM, Fisch T et al: Insulin-like growth factor binding protein 2 (IGFBP-2) separates hypertrophic and hyperplastic effects of growth hormone (GH)/IGF-I excess on adrenocortical cells in vivo. FASEB J 2002; 16: 1721-1731.
39. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C: Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000; 9: 765-768.
40. Zhou X, Hampel H, Thiele H et al: Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001; 358: 210-211.
41. Smith JM, Kirk EP, Theodosopoulos G et al: Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 2002; 39: 937-940.
42. Barker K, Martinez A, Wang R et al: PTEN mutations are uncommon in Proteus syndrome. J Med Genet 2001; 38: 480-481.
43. Biesecker LG, Rosenberg MJ, Vacha S, Turner JT, Cohen MM: PTEN mutations and proteus syndrome. Lancet 2001; 358: 2079-2080.
44. Happle R: Elattoproteus syndrome: delineation of an inverse form of Proteus syndrome. Am J Med Genet 1999; 84: 25-28.
45. Wang Y, Spatz MK, Kannan K et al: A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci USA 1999; 96: 4455-4460.
46. Jonkman MF, Scheffer H, Stulp R et al: Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 1997; 88: 543-551.